FDA panel endorses GRAIL’s multi-cancer early detection test

The panel voted 7-2 vote in favour of GRAIL’S Galleri multi-cancer early detection (MCED) test’s benefits outweighing its risks. The panel voted 7-2 vote in favour of GRAIL’S Galleri multi-cancer early detection (MCED) test’s benefits outweighing its risks. GRAIL submitted its PMA application to the FDA in January 2026. Credit: PJ McDonnell/Shutterstock.com A US Food and Drug Administration (FDA) advisory panel has voted in favour of approving GRAIL’s Galleri, cuing up a potential landmark approval for the multi-cancer early detection (MCED) test. In three separate votes, the 10 voting members of the FDA’s Molecular and Clinical Genetics Devices advisory panel…

Source: Medical Device Network